Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Parkinson's Disease (PD) is a neurodegenerative disorder often preceded by gastrointestinal dysfunction. Mutations in leucine-rich repeat kinase 2 (LRRK2) are known risk factors for both PD and inflammatory bowel disease (IBD), suggesting a link between PD and the gastrointestinal tract. Using single-cell RNA-sequencing and spectral flow cytometry, we demonstrated that the Lrrk2 Gly2019Ser (G2019S) mutation is associated with an increased neutrophil presence in the colonic lamina propria during Citrobacter rodentium infection. This concurred with a Th17 skewing, upregulated Il17a, and greater colonic pathology during infection. In vitro experiments showed enhanced kinase-dependent neutrophil chemotaxis and neutrophil extracellular trap (NET) formation in Lrrk2 G2019S mice compared to wild-type counterparts. Our results add to the understanding of LRRK2-driven immune cell dysregulation and its contribution to PD, offering insights into potential biomarkers for early diagnosis and intervention in PD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397289 | PMC |
| http://dx.doi.org/10.1038/s41531-025-01077-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lrrk2 G2019S mutation incites increased cell-intrinsic neutrophil effector functions and intestinal inflammation in a model of infectious colitis.
NPJ Parkinsons Dis
August 2025
Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada.
Parkinson's Disease (PD) is a neurodegenerative disorder often preceded by gastrointestinal dysfunction. Mutations in leucine-rich repeat kinase 2 (LRRK2) are known risk factors for both PD and inflammatory bowel disease (IBD), suggesting a link between PD and the gastrointestinal tract. Using single-cell RNA-sequencing and spectral flow cytometry, we demonstrated that the Lrrk2 Gly2019Ser (G2019S) mutation is associated with an increased neutrophil presence in the colonic lamina propria during Citrobacter rodentium infection.
View Article and Find Full Text PDFComparative Molecular Dynamics Reveals How LRRK2 Inhibitors Distinguish G2019S from Wild-Type.
Neurochem Res
August 2025
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, 50603, Malaysia.
Leucine-rich repeat kinase 2 (LRRK2) has become a critical drug target in Parkinson's disease, with mutation-selective inhibitors offering promising potential for precision medicine. However, the structural similarity between G2019S and wild-type kinases presents a significant challenge in developing selective inhibitors. Although recent advances have led to inhibitors that selectively target G2019S or wild-type kinases, the selectivity mechanism of these inhibitors remains unclear.
View Article and Find Full Text PDFStable two-year longitudinal clinical outcomes in LRRK2 G2019S non-manifest carriers in a remote nationwide study.
Parkinsonism Relat Disord
September 2025
Department of Neurology, University of Rochester Medical Center, NY, USA; Center for Health + Technology, University of Rochester Medical Center, NY, USA. Electronic address:
Background: Interest in Parkinson's disease (PD) prevention trials is growing, and genetically at-risk individuals may be ideal candidates. LRRK2 G2019S is the most common autosomal dominant genetic cause of PD and exhibits incomplete penetrance.
Objective: In a remote, prospective cohort study of LRRK2 G2019S carriers without PD, we examined change over time to better understand the natural history of LRRK2 PD.
Ergothioneine Treatment Ameliorates the Pathological Phenotypes of Parkinson's Disease Models.
J Neurochem
July 2025
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Ergothioneine (ET) is a naturally occurring thiol/thione that possesses several cytoprotective properties. Multiple studies suggest a potential neuroprotective role for ET. Here, we show in various Parkinson's disease (PD) models that ET is indeed neuroprotective.
View Article and Find Full Text PDFLRRK2 kinase modulates glucose-stimulated insulin secretion via RAB8 phosphorylation and ciliogenesis.
Cell Mol Life Sci
July 2025
Laboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via Trentacoste 2, 20134, Milan, Italy.
Leucine-rich repeat kinase 2 (LRRK2) encodes a multidomain protein whose mutations have been identified as genetic risk factors for Parkinson's disease (PD), an age-related neurodegenerative disorder. Outside the nervous system, LRRK2 is expressed in multiple tissues, including the endocrine pancreas, but its role here is unknown. Using pharmacological and molecular approaches, we show that LRRK2 kinase activity regulates stimulated insulin secretion by influencing secretory granule trafficking.
View Article and Find Full Text PDF